Advertisement

Topics

Phase 3 Study Evaluating the Safety and Efficacy of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint

06:15 EDT 5 Jul 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Opdivo (nivolumab) demonstrates superior recurrence-free survival versus Yervoy (ipilimumab) in Adjuvant Setting in CheckMate -238 Bristol-Myers Squibb Company (NYSE:BMY) announced today that a Phase 3 study evaluatin...

Other Sources for this Article

Bristol-Myers Squibb Company
Media:
Audrey Abernathy, cell: 919-605-4521
audrey.abernathy@bms.com
or
Investors:
Bill Szablewski, 609-252-5894
william.szablewski@bms.com
or
Tim Power, 609-252-7509
timothy.power@bms.com

NEXT ARTICLE

More From BioPortfolio on "Phase 3 Study Evaluating the Safety and Efficacy of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...